{"id":320221,"date":"2026-10-21T13:21:30","date_gmt":"2026-10-21T07:51:30","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=320221"},"modified":"2026-10-21T13:21:30","modified_gmt":"2026-10-21T07:51:30","slug":"hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/","title":{"rendered":"3 Hospital Pharma, Generic Formulations and Domestic Brands Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma: ROE of 11.7% to 18.7% and FY22 to FY26 revenue CAGR of 11.8% to 16.4%. Prices as of 20 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three formulation pharma stocks to watch are Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma. Their return on equity ranges from 11.7% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.8% to 16.4%. Emcure Pharmaceuticals has the highest return on equity at 18.7%, while Mankind Pharma has the fastest revenue growth at 16.4% a year. Prices are based on the 20 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Formulation pharma stocks follow companies that make finished medicines for patients, whether sold through hospitals, pharmacies or export markets. Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma cover hospital-focused and specialty products, generic formulations and a large domestic brand portfolio.<\/p>\n<p>This list covers three formulation pharma stocks with complete current figures: Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#What_Are_Formulation_Pharma_Stocks\" title=\"What Are Formulation Pharma Stocks?\">What Are Formulation Pharma Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#Formulation_Pharma_Stocks_at_a_Glance\" title=\"Formulation Pharma Stocks at a Glance\">Formulation Pharma Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#Why_Do_Formulation_Pharma_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Formulation Pharma Stocks Have a Strong Roadmap in India?\">Why Do Formulation Pharma Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#Why_Emcure_Pharmaceuticals_Features_Among_These_Formulation_Pharma_Stocks\" title=\"Why Emcure Pharmaceuticals Features Among These Formulation Pharma Stocks\">Why Emcure Pharmaceuticals Features Among These Formulation Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#Why_Strides_Pharma_Science_Features_Among_These_Formulation_Pharma_Stocks\" title=\"Why Strides Pharma Science Features Among These Formulation Pharma Stocks\">Why Strides Pharma Science Features Among These Formulation Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#Why_Mankind_Pharma_Features_Among_These_Formulation_Pharma_Stocks\" title=\"Why Mankind Pharma Features Among These Formulation Pharma Stocks\">Why Mankind Pharma Features Among These Formulation Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#Emcure_Pharmaceuticals_vs_Strides_Pharma_Science_vs_Mankind_Pharma_on_Key_Financials\" title=\"Emcure Pharmaceuticals vs Strides Pharma Science vs Mankind Pharma on Key Financials\">Emcure Pharmaceuticals vs Strides Pharma Science vs Mankind Pharma on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#Key_Risks_to_Check_Before_Investing_in_Formulation_Pharma_Stocks\" title=\"Key Risks to Check Before Investing in Formulation Pharma Stocks\">Key Risks to Check Before Investing in Formulation Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#Final_Thoughts_on_Formulation_Pharma_Stocks\" title=\"Final Thoughts on Formulation Pharma Stocks\">Final Thoughts on Formulation Pharma Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#What_are_formulation_pharma_stocks\" title=\"What are formulation pharma stocks?\">What are formulation pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#Which_formulation_pharma_stocks_are_covered_in_this_list\" title=\"Which formulation pharma stocks are covered in this list?\">Which formulation pharma stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#Why_do_formulation_pharma_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do formulation pharma stocks have a strong future roadmap in India?\">Why do formulation pharma stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#How_has_Emcure_Pharmaceuticals_performed_financially\" title=\"How has Emcure Pharmaceuticals performed financially?\">How has Emcure Pharmaceuticals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#How_has_Strides_Pharma_Science_performed_financially\" title=\"How has Strides Pharma Science performed financially?\">How has Strides Pharma Science performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#How_has_Mankind_Pharma_performed_financially\" title=\"How has Mankind Pharma performed financially?\">How has Mankind Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#What_risks_should_investors_check_before_buying_formulation_pharma_stocks\" title=\"What risks should investors check before buying formulation pharma stocks?\">What risks should investors check before buying formulation pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/hospital-pharma-generic-formulations-and-domestic-brands-stocks-roadmap-catalyst-list\/#Is_this_list_of_formulation_pharma_stocks_investment_advice\" title=\"Is this list of formulation pharma stocks investment advice?\">Is this list of formulation pharma stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Formulation_Pharma_Stocks\"><\/span><strong>What Are Formulation Pharma Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Formulation pharma stocks are listed companies that turn active ingredients into tablets, capsules, injectables and other finished doses. They earn from brand sales, hospital supply and generic exports, so their mix of markets shapes their growth and margins.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Formulation_Pharma_Stocks_at_a_Glance\"><\/span><strong>Formulation Pharma Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/emcure\/emcure-pharmaceuticals-ltd-share-price-today\">Emcure Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,766.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33,487<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">32.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.31<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/star\/strides-pharma-science-ltd-share-price-today\">Strides Pharma Science<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,029.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,491<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.57<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/mankind\/mankind-pharma-ltd-share-price-today\">Mankind Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,253.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">93,014<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">45.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.39<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Emcure Pharmaceuticals and Strides Pharma Science trade at a P\/E below the industry P\/E, while Mankind Pharma trades above it, which reflects the growth the market already expects. Readers comparing formulation pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Formulation_Pharma_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Formulation Pharma Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Formulation pharma stocks have a strong roadmap in India because domestic medicine use is rising and Indian makers continue to win share in regulated export markets.<\/p>\n<ul>\n<li><strong>Domestic demand.<\/strong> Higher incomes and insurance cover increase medicine use across therapies.<\/li>\n<li><strong>Export markets.<\/strong> Generic approvals in regulated markets open large, repeat demand.<\/li>\n<li><strong>Hospital channel.<\/strong> Injectables and specialty products supplied to hospitals carry steady volumes.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Emcure_Pharmaceuticals_Features_Among_These_Formulation_Pharma_Stocks\"><\/span><strong>Why Emcure Pharmaceuticals Features Among These Formulation Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the formulation pharma stocks on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.<\/p>\n<p>Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%.<\/p>\n<p>In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P\/E of 32.9, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> It is strengthening its domestic branded portfolio in women&#8217;s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.<\/p>\n<p><strong>What to watch:<\/strong> Look at the growth of the India branded business and the pace of new launches abroad.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Strides_Pharma_Science_Features_Among_These_Formulation_Pharma_Stocks\"><\/span><strong>Why Strides Pharma Science Features Among These Formulation Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the generic pharma shares on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.<\/p>\n<p>In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%.<\/p>\n<p>Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P\/E of 15.0, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.<\/p>\n<p><strong>What to watch:<\/strong> Track new US launches and the pace of price erosion in generic categories.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Mankind_Pharma_Features_Among_These_Formulation_Pharma_Stocks\"><\/span><strong>Why Mankind Pharma Features Among These Formulation Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Mankind Pharma is one of India&#8217;s largest pharmaceutical companies by domestic sales, with a strong presence in chronic and acute therapies, consumer healthcare brands and a large field force.<\/p>\n<p>The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P\/E of 45.0, above the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.<\/p>\n<p><strong>What to watch:<\/strong> Watch the market share in chronic therapies and the integration of acquired brands.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Emcure_Pharmaceuticals_vs_Strides_Pharma_Science_vs_Mankind_Pharma_on_Key_Financials\"><\/span><strong>Emcure Pharmaceuticals vs Strides Pharma Science vs Mankind Pharma on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three formulation pharma stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Emcure Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,919<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,335<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">941<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Strides Pharma Science<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,202<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,009<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.8%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">575<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.5%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Mankind Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,978<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14,636<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,938<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.2%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Emcure Pharmaceuticals posts the highest return on equity in this group at 18.7%. Mankind Pharma combines the largest FY26 revenue at Rs 14,636 crore with the fastest revenue growth, a 16.4% compound annual rate. A useful habit with formulation pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Emcure Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,104<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,583<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.7%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Strides Pharma Science<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,128<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,270<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Mankind Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,650<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,076<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.7%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Formulation_Pharma_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Formulation Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these formulation pharma stocks, the main points are: Long-term generic pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Pricing pressure.<\/strong> Price controls and generic competition can limit margins.<\/li>\n<li><strong>Regulatory checks.<\/strong> Inspections at plants can delay launches.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter formulation pharma stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Formulation_Pharma_Stocks\"><\/span><strong>Final Thoughts on Formulation Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Formulation pharma stocks fit investors who prefer finished-product businesses with brand or distribution strength. Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma each have a defined route to market. Based on the 20 October 2026 close, Emcure Pharmaceuticals trades at Rs 1,766.6, Strides Pharma Science at Rs 1,029.3 and Mankind Pharma at Rs 2,253.2. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these formulation pharma stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track formulation pharma stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_formulation_pharma_stocks\"><\/span><strong>What are formulation pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Formulation pharma stocks are listed companies that turn active ingredients into tablets, capsules, injectables and other finished doses. They earn from brand sales, hospital supply and generic exports, so their mix of markets shapes their growth and margins. This list looks at three of them, Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_formulation_pharma_stocks_are_covered_in_this_list\"><\/span><strong>Which formulation pharma stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma. Based on the 20 October 2026 close, Emcure Pharmaceuticals traded at Rs 1,766.6, Strides Pharma Science at Rs 1,029.3 and Mankind Pharma at Rs 2,253.2. Their return on equity ranges from 11.7% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.8% to 16.4%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_formulation_pharma_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do formulation pharma stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Formulation pharma stocks have a strong roadmap in India because domestic medicine use is rising and Indian makers continue to win share in regulated export markets. The main drivers are as follows. Domestic demand. Higher incomes and insurance cover increase medicine use across therapies. Export markets. Generic approvals in regulated markets open large, repeat demand. Hospital channel. Injectables and specialty products supplied to hospitals carry steady volumes. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Emcure_Pharmaceuticals_performed_financially\"><\/span><strong>How has Emcure Pharmaceuticals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P\/E of 32.9, below the industry P\/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women&#8217;s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Strides_Pharma_Science_performed_financially\"><\/span><strong>How has Strides Pharma Science performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P\/E of 15.0, below the industry P\/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Mankind_Pharma_performed_financially\"><\/span><strong>How has Mankind Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P\/E of 45.0, above the industry P\/E of 36.0. Looking ahead, the company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_formulation_pharma_stocks\"><\/span><strong>What risks should investors check before buying formulation pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying formulation pharma stocks. Pricing pressure. Price controls and generic competition can limit margins. Regulatory checks. Inspections at plants can delay launches. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_formulation_pharma_stocks_investment_advice\"><\/span><strong>Is this list of formulation pharma stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are formulation pharma stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Formulation pharma stocks are listed companies that turn active ingredients into tablets, capsules, injectables and other finished doses. They earn from brand sales, hospital supply and generic exports, so their mix of markets shapes their growth and margins. This list looks at three of them, Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which formulation pharma stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma. Based on the 20 October 2026 close, Emcure Pharmaceuticals traded at Rs 1,766.6, Strides Pharma Science at Rs 1,029.3 and Mankind Pharma at Rs 2,253.2. Their return on equity ranges from 11.7% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.8% to 16.4%.\"}},{\"@type\":\"Question\",\"name\":\"Why do formulation pharma stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Formulation pharma stocks have a strong roadmap in India because domestic medicine use is rising and Indian makers continue to win share in regulated export markets. The main drivers are as follows. Domestic demand. Higher incomes and insurance cover increase medicine use across therapies. Export markets. Generic approvals in regulated markets open large, repeat demand. Hospital channel. Injectables and specialty products supplied to hospitals carry steady volumes. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Emcure Pharmaceuticals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P\/E of 32.9, below the industry P\/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women's health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.\"}},{\"@type\":\"Question\",\"name\":\"How has Strides Pharma Science performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P\/E of 15.0, below the industry P\/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.\"}},{\"@type\":\"Question\",\"name\":\"How has Mankind Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P\/E of 45.0, above the industry P\/E of 36.0. Looking ahead, the company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying formulation pharma stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying formulation pharma stocks. Pricing pressure. Price controls and generic competition can limit margins. Regulatory checks. Inspections at plants can delay launches. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of formulation pharma stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Formulation Pharma Stocks with a strong future roadmap: Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.<\/p>\n","protected":false},"author":28,"featured_media":320220,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,13906,13907,13904,13905,805,9049],"class_list":["post-320221","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-branded-pharma-stocks","tag-emcure-pharmaceuticals","tag-formulation-pharma-stocks","tag-generic-pharma-shares","tag-mankind-pharma","tag-strides-pharma-science"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["320220"],"rank_math_title":["Formulation Pharma Stocks With a Strong Roadmap"],"rank_math_description":["Compare 3 formulation pharma stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 20 Oct 2026."],"rank_math_focus_keyword":["formulation pharma stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-hospital-pharma-generic-formulations-and-domestic-brands-stocks-with-a-strong.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/320221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=320221"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/320221\/revisions"}],"predecessor-version":[{"id":320222,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/320221\/revisions\/320222"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/320220"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=320221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=320221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=320221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}